Further analysis of each treatment arm separately indicated that lower HIF-1α percent of tumor expression was statistically significantly associated with improvements in both TTP and PFS in the Schedule 4/2 group; however, these associations were not statistically significant in the CDD group. This evidence concerns the gene HIF1A and neoplasm.